title: Comments on the paper showing an exceptionally favorable response to tofacitinib among Japanese rheumatoid patients and an issue surrounding clinical trial led by pharmaceutical company.
authors.affiliation: Division of Rheumatology and Clinical Immunology, Jichi Medical University , Shimotsuke-shi, Tochigi-ken , Japan.
authors.forename: Seiji
authors.initials: S
authors.lastname: Minota
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*
chemical_list: D018501:Antirheumatic Agents; D011743:Pyrimidines; D011758:Pyrroles; D008727:Methotrexate
keywords: Clinical trial; DMARD; Odds ratio; Tofacitinib